| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids | $ Total Asks | # Bids | # Asks | Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Zephyr AI | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $129.71MM | Series A | 3/13/2024 | $69.01MM | $482.26MM | $17.34 | Revolution Growth, Eli Lilly and Company, Jeff Skoll, EPIQ Capital Group | ||||
 | Glooko | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $521.83MM | Series F | 10/10/2024 | $100MM | $475.64MM | $2.42 | Georgian Partners, Health Catalyst Capital, Canaan | ||||
 | Diagonal Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $253MM | Series B | 1/8/2026 | $125MM | $447.42MM | $2.70 | Sanofi Ventures, Janus Henderson Investors, Deep Track Capital, EcoR1 Capital, Logos Capital, Balyasny Asset Management, Woodline Partners, BVF Partners, Atlas Venture, Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, Velosity Capital, Checkpoint Capital, RV Invest, Biovision Ventures | ||||
 | CoRegen | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $131.75MM | Series B-1 | 10/28/2025 | $13.5MM | $437.24MM | $18.00 | Undisclosed Investors | ||||
 | Shepherd | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $66.65MM | Series B | 3/24/2026 | $42MM | $424.84MM | $15.52 | Intact Private Capital, Spark Capital, Costanoa Ventures | ||||
 | Atavistik | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $260MM | Series B-1 | 3/5/2026 | $40MM | $422.55MM | $1.20 | RA Capital Management | ||||
 | Spinogenix | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $24.4MM | Series D | 11/21/2025 | $9.8MM | $365.97MM | $34.92 | Undisclosed Investors | ||||
 | Atsena Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $235.9MM | Series C-3 | 4/2/2025 | $60MM | $337.46MM | $4.13 | Bain Capital, Wellington Management, Lightstone Ventures, Sofinnova Investments, Abingworth, Foundation Fighting Blindness, Hatteras Venture Partners, Osage University Partners, Manning Family Foundation | ||||
 | Baylor Genetics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $102MM | Series A | 3/31/2025 | $102MM | $326MM | $17.88 | Decheng Capital | ||||
 | Phil | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $119.43MM | Series D | 7/3/2021 | $61.34MM | $321.12MM | $4.06 | Warburg Pincus | ||||
 | Lumicell | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $125.44MM | Series BB | 5/6/2025 | $44.14MM | $294.79MM | $1.16 | Undisclosed Investors | ||||
 | Alveus Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $202.01MM | Series A | 2/24/2026 | $197MM | $290.11MM | $20.00 | New Rhein Healthcare Investors, Andera Partners, Omega Funds, Sanofi Capital, Kurma Partners, Avego Management, Jeito Capital, Novo Holdings, Agent Capital, Seroba Lifesciences, Global BioAccess Fund | ||||
 | TRexBio | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $218.62MM | Series B | 1/27/2026 | $134.06MM | $268.67MM | $3.09 | Janus Henderson Investors, Balyasny Asset Management, Affinity Asset Advisors, Delos Capital, Avego BioScience Capital, Agent Capital, Eli Lilly and Company, SV Health Investors, Pfizer Ventures, Johnson & Johnson Innovation, Alexandria Venture Investments, Polaris Partners | ||||
 | Ionetix | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $98.68MM | Series F | 8/7/2024 | $62.72MM | $266.93MM | $1.40 | Eli Lilly, POINT Biopharma Global | ||||
 | TRIANA Biomedicines | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $230.06MM | Series B | 12/3/2025 | $120.06MM | $262.22MM | $3.04 | Ascenta Capital, Bessemer Venture Partners, YK Bioventures, Regeneron Ventures, Invus, Finchley Healthcare Ventures, RA Capital Management, Atlas Venture, Lightspeed Venture Partners, Pfizer Ventures, Surveyor Capital | ||||
 | Mesh Optical Technologies | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $50MM | Series A-1 | 2/17/2026 | $37.93MM | $253.44MM | $16.17 | Thrive Capital, Also Capital, Banner Ventures | ||||
 | Edison Scientific | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $68.89MM | Series Seed | 12/18/2025 | $51MM | $244.55MM | $16.59 | Triatomic Capital, Spark Capital, Pillar, Susa Ventures, Striker Venture Partners, Hawktail, Olive Capital | ||||